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Abstract 
Background  
Growth failure is well-recognised in pediatric Inflammatory Bowel Disease (PIBD; <18 
years). We aimed to examine whether anti-Tumor Necrosis Factor (TNF) therapy improves 
growth in a PIBD population-based cohort.  
Methods  
A retrospective review of all Scottish children receiving anti-TNF (infliximab (IFX) and 
adalimumab (ADA)) from 2000-2012 was performed; height was collected at: 12 months 
before anti-TNF (T-12), start (T0) and 12 (T+12) months after anti-TNF.  
Results 
93/201 treated with IFX and 28/49 for ADA had satisfactory growth data; 66 had full 
pubertal data.  Univariate analysis demonstrated early pubertal stages (Tanner 1-3 n=44 vs. 
T4-5 n=22), disease remission, disease duration ≥2 years and duration of IFX ≥12 months 
were associated with improved linear growth for IFX; for ADA only improvement was seen 
in Tanner 1-3. For IFX, Tanner 1-3 median Δ ht SDS -0.3 (-0.7,0.2) at T0 changed to 0.04 (-
0.5, 0.7) at T+12 (p<0.001) vs -0.01 (-0.5, 0.9) at T0 in T4-5 changed to-0.01 (-0.4, 0.2) at 
T+12 (p>0.05). For IFX disease duration ≥2 year, median Δ ht SDS was -0.13 (-0.6, 0.3) at 
T0 then 0.07 (-0.3, 0.6) at T+12 (p<0.001). Remission improved Δ ht SDS (median Δ ht SDS 
-0.14 (-0.6, 0.3) at T0 to 0.17 (-0.2, 0.7) at T+12 (p<0.001)). Multiple regression analysis 
demonstrated corticosteroid usage at T0 predicted improved Δ ht SDS at T+12 for IFX and 
ADA. 
Conclusions: Anti-TNF therapy is more likely to be associated with growth improvement 
when used at earlier stages of puberty with remission a key growth-promoting strategy in 
Paediatric Crohn’s disease. 
Keywords: Inflammatory Bowel Disease, Infliximab, growth 
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What is known 
•       Growth is adversely affected in active IBD especially Crohn’s disease 
•       Infliximab and Adalimumab are associated with improvement in short term 
growth with most studies being multicentre and non-population based 
What is new 
•       Children who are treated with greater than 12 months of Infliximab, achieve remission 
post induction and are in the early stages of puberty demonstrate improved linear growth 
•       Children with disease duration at the start of Infliximab of greater than 2 years 
demonstrated improved linear growth compared to those with disease for less than 2 years 
•       Combination therapy with Infliximab and Azathioprine results in greater improvement 
in linear growth 
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Introduction 
The treatment of pediatric Inflammatory Bowel Disease (PIBD) has evolved 
significantly in recent years with the advent of anti-Tumor Necrosis Factor (TNF) therapy 
reducing inflammation, improving mucosal healing and reducing disease 
relapse/corticosteroid usage, however finding a therapy which can improve long term linear 
growth has proven more elusive
1-3
. The presence of poor growth and short stature in PIBD, 
and more specifically, Crohn’s Disease (CD) has been described for some time; this can lead 
to a significant impact on final adult height with varying reports of 20-30% of children with 
CD having a reduced adult height
4
. The potential reasons for this negative effect on growth 
are likely to be multifactorial and include: malabsorption, decreased oral intake, uncontrolled 
inflammation,  increased requirements and losses of energy and nutrients; this can often be 
exacerbated by impaired growth which can precede clinical symptoms in 42% of children
5
.  
Further research into the mechanisms surrounding growth failure have shown a modulatory 
role of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNFα) and 
interleukins (IL)  as well as a degree of growth hormone resistance
6,7
. 
As anti-TNF therapy usage has increased,  the evidence on the long-term efficacy has 
improved 
8
. Despite further evidence and better understanding, many issues have yet to be 
resolved including identifying patients likely to have a prolonged treatment response and then 
balancing the risk/benefit of combination therapy with anti-TNF and immunomodulator vs 
monotherapy with anti-TNF therapy alone. The two most commonly used anti-TNF agents in 
PIBD are Infliximab (IFX) and Adalimumab (ADA). Both have both been shown to be 
effective in the induction and maintenance of remission for pediatric CD and similarly for 
infliximab in Ulcerative Colitis (UC)
1,9-11
. The evidence on the efficacy of Infliximab (IFX) 
on short term growth is generally supportive with several studies showing clear benefit 
12-16
 
however other published studies have shown no beneficial effect 
17-20
. A  recent systematic 
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review on pediatric anti-TNF therapy concluded that IFX did have a positive effect on growth 
in CD, particularly in pre or early puberty but did not mention growth outcomes of those 
treated with ADA
21
. Fewer growth data exist on ADA but ADA does also demonstrate an 
improvement in short term 
22
and long term growth
10
 more pronounced in those who enter 
remission
23
.   
The aim of this study was to characterise growth in a population-based cohort of 
children with all types of IBD, treated with ADA and/or IFX between 2000-2012 in Scotland, 
using data from the Scottish PIBD biologicals register. 
 
Methods 
 
Data were gathered from the 3 regional Pediatric Gastroenterology, Hepatology and 
Nutrition (PGHAN) shared care networks (West, South-East and North of Scotland,) 
involving all 3 tertiary PGHAN centres (Glasgow, Edinburgh and Aberdeen) and all pediatric 
units in district general hospitals, which form a Scottish PGHAN managed service network, 
covering all PIBD patients in pediatric services.   
  
Case identification 
All PIBD patients within pediatric services were included in the Scottish Pediatric 
Biologicals Registry if aged <18 years at biological therapy start from 01/01/2000 to 
31/12/2012 with 10 weeks minimum follow up, as previously described
24
. Patients were 
included who had growth data available for a minimum of 24 months; 12 months prior to 
commencing anti-TNF therapy and for 12 months after treatment commenced, if further 
growth data was available this was also captured.  Data on some of the patients within the 
current study have been included in previous related publications 
2,11,23
. Patients were given 
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IFX for fistulating CD outside of the licenced indications. One patient was excluded as was 
receiving recombinant human growth hormone as growth promoting treatment. Drug 
administration and dose adjustment was given as previously described
24
 . 
 
Data collection 
Data were collected as previously described on demographics including disease 
phenotype as per the Montreal criteria
25
; biological schedule and regimen (induction only; 
induction then maintenance); medications (including corticosteroids, thiopurines and 
methotrexate) and surgery before, at and after biological start
24
. Disease activity was assessed 
by physician global assessment (PGA) through history, clinical examination, anthropometry 
and laboratory values by the clinician and divided into quiescent (remission), mild, and 
moderate/severe. A treatment course was defined as the duration of each anti-TNF agent the 
patient received. 
 
Data were collected until study end on 31/03/2013 unless prior transition to adult 
services or emigration from Scotland. Height and weight data were collected for IFX over 48 
months for all PIBD subtypes (CD, UC, IBDU) at the following time points: 12 months prior 
to commencing IFX (T-12), at start of IFX (T0), 12 (T+12),24 (T+24) and 36 (T+36) months 
post IFX start). Due to transition and variable length of follow up for each patient, a smaller 
cohort had growth data available for 24 and 36 months post start of IFX (Figure 1). For 
ADA, height and weight data were collected over 24 months (at 12 (T-12) and 6 months prior 
to commencing ADA(T-6) at start of ADA (T0), 6 (T+6) and 12 months (T+12) post ADA). 
Satisfactory growth data reflects 12 months prior to commencing anti-TNF therapy to 12 
months after start date whilst extended growth data covers data collected up to 36 months 
after starting anti-TNF therapy. 
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 Height was measured using wall mounted stadiometers according to Frankfurt plane 
position and weight measured wearing minimal clothing using calibrated seat scales to the 
nearest 100g. These data were converted to standard deviation scores for height (Ht SDS), 
weight (Wt SDS) and BMI (BMI SDS) using 1990 British childhood standards
26,27
, then Δ 
height SDS (Δ ht SDS) and height velocity(HV) were calculated for T0 and T+12. Delta ht 
SDS at T0 was calculated by subtracting the ht SDS at T0 from ht SDS at T-12, for delta ht 
SDS at T+12 then ht SDS at T12 was subtracted from ht SDS at T0.  Pubertal staging was 
assessed using either a validated self-assessment  form or by clinical examination
28,29
 and was 
documented at baseline, 12, 24 and 36 months where available.  
 
Ethical approval is not required in NHS Scotland for retrospective case record reviews 
with examination of departmental databases of service design/delivery, such as in PISA (the 
Paediatric-onset IBD Scottish Audit), comprising epidemiology 
30
 and the Scottish PIBD 
biologicals register
24
. 
 
Statistics 
Descriptive statistics are presented as median with 90
th
 percentiles. Wilcoxon was 
used to examine differences in height, weight and BMI SDS scores. A standard significance 
level of 0.012 was adopted due to multiple comparison testing and was calculated using a 
Bonferroni correction. Analyses were carried out using SPSS (IBM 19, Chicago Ill) IBM. 
Multiple logistic regression was performed using R v3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria) and all patients with satisfactory growth data were combined. 
Confounders including type of IBD, small bowel involvement, azathioprine use, methotrexate 
use, duration of disease, Tanner pubertal staging, remission, corticosteroid use at baseline, 
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PGA at baseline, height SDS at baseline and whether patients received maintenance therapy 
with anti-TNF were entered into the model. There was a degree of duplication in the data as 
certain patients received both IFX and ADA so for those patients, one of the treatment 
periods was randomly excluded to ensure a robust model with no autocorrelation.  A general 
linear model was used; a correction was performed to minimise the effect of missing Tanner 
staging data using the adjusted general linear model. 
Results 
 
General characteristics 
One hundred and ninety-five patients were included in the initial cohort who were 
treated with 240 courses of therapy with a biologic, 164 (85%) had CD, 28 (14%) had UC 
and 3 (1%) Inflammatory Bowel Disease Unclassified (IBDU). Most, 115 (60%) were boys 
with a median age of 11.2 years (range 2.7-17.2) at diagnosis. 191 received IFX and 49 
received ADA (4 received ADA alone).  
Infliximab cohort 
Satisfactory 24-month growth data were available for 93/191 (49%) (see Figure 1); 
57 (61%) were boys and 86 (92%) had CD with 7 (8%) having UC. Median age at diagnosis 
was 10.4 years (range 2.7-15.2) and median age at start of IFX was 13.8 years (range 5.9-
17.6). In the 93 where satisfactory growth data were available for 24 months, the most 
common disease location in CD was panenteric in 28 (33%) children with inflammatory the 
most common behaviour in 76 (88%) whilst 86% had extensive UC. The commonest 
indication for starting IFX was active luminal disease followed by immunomodulator failure 
in CD whilst for UC it was chronic active colitis followed again by immunomodulator failure 
(see Table 1). At treatment start 18% had Ht SDS <-2, improving only to 15% then 7% at 1 
year and 2 years respectively after treatment with IFX (p>0.05). Forty-one patients underwent 
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surgery (18 pre IFX); all of whom had CD. Most patients had disease for greater than 2 years 
(n=62) having a median duration of 3.5yrs prior to starting IFX whilst those <2yrs (n=31) had 
their disease for 1.3yrs. Pubertal data were available in 65/93. 
 
Sixty-six patients received further IFX post induction, including 6 patients who 
received episodic dosing prior to 2007, with 42 subsequently discontinuing maintenance IFX 
after a median of 1.0 years (range 0.2-3.2) receiving a median of 8 doses (range 1-25) (see 
Figure 1). The most common reasons for discontinuation of those on maintenance IFX were 
loss of response in 15, planned drug withdrawal in 13, primary non-response in 8, 5 had an 
allergic reaction and 1 had an adverse event. Thirty (45%), all with CD, required dose 
escalation, most commonly increased frequency in 23 (77%) whilst 22 (73%) had an 
increased dose. 
 
In the 93 children with satisfactory 24 month growth data, median Ht SDS at T-12 
was -0.7 (-2.2,-0.7), worsened to median Ht SDS -0.8 (-2.5,-0.5) at T0 and remained similar 
with a median Ht SDS -0.8 (-2.3,0.7) at T+12 (p<0.001). Median Δ Ht SDS was -0.2 (-
0.6,0.3) at T0 and increased to a median Δ Ht SDS at T+12 of 0.1 (-0.4,0.6) (p<0.001). 
Median HV at T0 was 3.5 (1.0, 7.2) cm/yr and which increased to 4.4 (1.2,9.1) at T12 
(p=0.003). No further sustained improvement in linear growth was seen beyond 12 months 
post-anti-TNF start in those who were followed up for 36 months, the extended growth 
cohort (see Table 2).  
 
Factors affecting growth 
Achieving remission was associated with a significant improvement in median Ht 
SDS, Δ Ht SDS and HV (see Figure 2). Early stages of puberty,                                                                                                                                                                                                                                                  
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Tanner stages 1-3, were associated with an increase in Δ Ht SDS and HV (see Figure 3).  
22/94 were Tanner stage 4-5 and showed no significant change in Ht SDS and Δ Ht SDS and 
a decrease in HV; Ht SDS at T0 -0.2 (-1.8,1.1) to -0.3 (-2.0, 1.1) at T+12 (p=0.78), Δ Ht SDS 
at T+0 -0.14 (-0.5, 0.9) then Δ Ht SDS at T+12 -0.01 (-0.5, 0.9) (p=0.78) and HV at T0 
3.5(1.0,9.8) decreased to 2.1 (0.2, 4.4) at T+12 (p=0.001).  60 (65%) of those treated with 
IFX had a disease duration greater than 2 years at the start of their treatment with IFX and 
had increased Ht SDS, Δ Ht SDS and HV at T+12 compared to those with disease duration 
less than 2 years (see Table 3). 
 
Boys growth improved compared to girls, with boys Δ Ht SDS and HV increasing 
significantly whilst girls only increased Δ Ht SDS (see Table 3). In those with moderate 
disease, improvement was noted in Δ Ht SDS and HV (see Table 3). 82 (88%) were on 
immunomodulators (IM) at baseline and increase in Ht SDS, Δ Ht SDS and HV at T+12 was 
noted in this cohort compared to no improvement in those not on IM. Further analysis was 
performed on type of immunomodulator, given that 42 patients were on azathioprine (AZA) 
and 40 on methotrexate (MTX); there was no significant difference between the AZA and 
MTX groups in  Δ Ht SDS at T+12 (p=0.64, 95%CI -0.2, 0.1). Azathioprine usage was 
associated with increased Ht SDS, Δ Ht SDS and HV compared to only improvement in Δ Ht 
SDS and HV in those on MTX (see Table 3).  
 
Patients who received induction and maintenance (n=66 (I&M)) showed improvement 
in Ht SDS, Δ Ht SDS and HV compared to those who received induction only where only Δ 
Ht SDS increased (n=37 (I only)).  Patients who were established on maintenance IFX for 
greater than 12 months from first induction dose had significantly increased Δ Ht SDS and 
HV (see Table 3). Corticosteroid use at baseline was associated with significant 
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improvement in Ht SDS and Δ Ht SDS (see Table 3). Increase was noted in Ht SDS, Δ Ht 
SDS, and HV in those who did not have surgery (n=68) whilst no significant improvement 
was observed in those who underwent surgery post-IFX (n=25) (see Table 3). No 
improvement in Ht was observed in those with Ulcerative Colitis (data available on request). 
 
General characteristics for Adalimumab 
Growth data for 12 months were available for 28 patients treated with ADA; 12 were girls, 27 
with CD (see Table 1) and 18 of whom had IFX growth data analysed previously. All 
patients treated with ADA increased Δ Ht SDS at 12 months only (see Supplemental Digital 
Content, Table 1, http://links.lww.com/MPG/A764). Early stages of puberty (Tanner stage 2 
and 3) were associated with increased Δ Ht SDS and HV and improvement was seen in Δ Ht 
SDS in males only (see Supplemental Digital Content, Table 2, 
http://links.lww.com/MPG/A764).  No improvement was seen in those who were not on 
corticosteroids at baseline (n=16) or those who achieved remission at week 4 (n= 5) (data 
available on request).   
 
Multiple regression  
Multiple regression models were used to determine associations of therapy and disease on Δ 
Ht SDS at T+12 for both IFX and ADA combined. The following variables were inserted into 
both models: Δ Ht SDS T0, remission, Tanner staging of puberty, azathioprine use, 
methotrexate use, corticosteroid usage at baseline, type of IBD, PGA at baseline, small bowel 
involvement, maintenance therapy given and duration of disease until anti-TNF commenced. 
In the final model only corticosteroid use at baseline was associated with an improvement in 
Δ Ht SDS at 12 months (p=0.02) (95%CI 0.03,0.39). 
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Discussion 
 
 In our Scottish population-based cohort of children with all subtypes of PIBD treated 
with either IFX or ADA, anti-TNF therapy was associated with improved linear growth as 
has been demonstrated in other population based cohorts for IFX 
31,32
; however, to our 
knowledge this is the first population-based ADA study.  At induction of IFX, 18% of 
children had a Ht SDS <-2, improving to 15% then 7% at 1 year and 2 years respectively 
after treatment.  We have also demonstrated that IFX therapy improved linear growth in those 
who achieved remission, had disease duration for over 2 years at anti-TNF start and were in 
the early stages puberty (Tanner stage 1-3).  In addition, we have also shown that improved Δ 
ht SDS at 12 months’ post-start of anti-TNF therapy is associated with corticosteroid use at 
baseline.  
The rates of growth failure seen in our cohort are similar to other population based 
cohorts of a similar size. In the largest population-based multicentre inception cohort from 
Northern France, around 10% of all newly diagnosed children with CD had severe growth 
failure (height SDS <-2 SDS),  improving only slightly to 8% at 1 year and 6.5% at 2 years
31
; 
however, no pubertal data were provided.  At diagnosis, children had a mean ht SDS of -
0.57+/-1.2 compared to -0.83+/-1.1 in our cohort. Rates of immunomodulation were similar 
in both cohorts but the median age at first IFX dose in the French group was 18 years 
contrasting with 13.2 years in our cohort (given data on PIBD cases in EPIMAD are collected 
both before and after transition to adult IBD services; time of transition is study end in the 
Scottish PIBD biologicals register); the younger age in our cohort may explain the increase in 
poor growth as the disease may have presented earlier so having an adverse effect at crucial 
point in the child’s growth. The two other nationwide population-based study examining use 
of IFX showed differing results; firstly De Ridder observed that in 6 CD patients with ht SDS 
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<1 at initiation of IFX, 3 subsequently resumed normal growth velocity who remained on 
IFX post induction
32
. However, Wewer showed that  in 10 CD patients who had IFX in part 
due to growth failure had  no improvement was noted in height velocity when compared 
before and after treatment (no pubertal data or ht SDS were provided for this cohort) 
18
.  
The effect of pubertal stage on linear growth change in children treated with IFX 
remains controversial. Initially growth was shown to be dependent on progression through 
puberty with no improvement seen in those Tanner 4 and 5 compared to Tanner 1-3, although 
it was noted that those in Tanner 1-3 grew at a suboptimal rate
12
. This was again 
demonstrated in a larger cohort of newly diagnosed patients in North America who were 
treated with IFX where greater improvement was seen in those in early puberty; the 
improvement in growth was hypothesised to be related to pubertal progress after initiation of 
IFX
17
.  This contrasts with the findings of Malik and colleagues who demonstrated improved 
HV SDS 6 months after IFX after analysis was adjusted for pubertal staging
2
. In our study, 
we observed similar results to Malik with improvement seen in Tanner 1 and in Tanner 2/3 in 
Δ height SDS and height velocity but we did not observe an improvement in height SDS in 
either group; this supports the theory that the improvement in growth is not only due to 
pubertal progression, with similar improvements seen in pre-pubertal children as those in 
puberty. A further theory is that IFX merely prevents further deterioration in height without 
improving overall height
33
. However, only half on those who were Tanner stage 1 at start of 
IFX remained Tanner 1 at 12 months which may have influenced their growth. 
Growth improves with greater disease control as can be seen in our results, where no 
improvement in growth was observed in those who did not achieve remission after induction. 
In those that achieved remission post-induction, improvement was seen in all measures of 
growth suggesting that these patients may demonstrate catch up growth now that the 
inflammatory process has been ‘switched off’ rather than the anti-TNF therapy agents 
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themselves. This has previously been demonstrated in the extension to the REACH study 
which followed patients up to 12 months and observed a trend towards continued 
improvement in height SDS score in those with sustained remission
34
. However, other 
therapies which have been proven to be highly successful at inducing remission, such as 
exclusive enteral nutrition, have not shown similar improvements in linear growth potentially 
due to the relatively short term effect of this treatment. 
An interesting finding of this study was the associated improvement in linear growth 
in those receiving corticosteroids at induction, most evidence would suggest that 
corticosteroid usage is associated with poor growth
35
 yet not in this cohort. There are several 
possibilities for this, one is that these children had received steroids prior to anti-TNF therapy 
and with the introduction of these agents corticosteroids were able to be weaned leading to 
improved growth
17
, another is that corticosteroid usage combined with anti-TNF therapy 
resulted in these children entering remission earlier consequently resulting in improved 
growth.  The definition of remission used in studies varies; some would define remission only 
as clinical resolution of symptoms, some combine this with specified disease activity indices 
(eg PCDAI <10), others  include normality of laboratory tests including faecal calprotectin, 
whilst the current definition of true remission for many now includes mucosal healing in 
addition to clinical and biochemical improvement
36
. Mucosal healing has been associated 
with prolonged remission after induction treatment with IFX
37
 and could potentially be 
associated with sustained improvement in linear growth too.  Potentially those who improved 
growth parameters only slightly despite being in clinical remission had not in fact achieved 
mucosal healing, which may then have continued to adversely affect their height.  Further 
evidence for improved growth after the inflammatory process has been stopped is the 
improved growth seen in those who continued on IFX for 12 months - these were patients 
who were more likely to have had a response and it is possible that the IFX in addition to 
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stopping the inflammatory process had an independent role in improving growth. A study 
which directly correlates the degree of mucosal healing and growth response to biologics 
would help address whether optimal growth outcomes need so-called ‘deep remission’. 
In our study, those who had disease for ≥ 2years had improved height SDS after 12 
months of treatment, Δ height SDS and height velocity compared to those with a shorter 
disease duration of less than 2 years. This contrasts with most current evidence which 
suggests that those with shorter disease duration have a better outcome when treated with 
anti-TNF; exemplars are the REACH study and ACCENT 1 trial. In the REACH study 
children had a median duration of disease of 1.6 years prior to IFX and had an 88% response 
and 59% remission rate post-induction contrasting with a 66.7% response and 39.1% 
remission rate in adults in ACCENT 1 trial where the median duration of disease was 7 years 
prior to initiation of IFX
1,38
. Further evidence is provided by another prospective multicentre 
North American study that observed improved growth and clinical outcome at 12 months of 
those treated with early IFX (within 3 months of diagnosis) compared with early 
immunomodulator therapy or no therapy
39
.  The reason for improved growth in those with a 
longer disease course in our cohort could be that the growth and/or pubertal development has 
been impaired for a prolonged period due to the cytokine-driven inflammatory process but 
when the inflammation is ‘switched off’ with anti-TNF therapy, improved growth is then 
seen.  
In our study, including all subtypes of IBD, we found a significant improvement in 
linear growth in those treated with combination therapy of AZA and IFX which contrasts 
with other studies examining the effect of AZA on growth. The only paediatric RCT on the 
use of AZA from 2000 observed no significant difference in linear growth between those 
treated with AZA and placebo at 18 months 
40
. This was confirmed by Pfefferkorn who found 
no improvement in height at 12 or 24 months for AZA
17
. However, a UK study did show 
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improved height with treatment with AZA but this was not statistically significant. Caution 
must be observed interpreting the results of this UK study as it was retrospective,  before IFX 
was commonly used and with growth data only available for 44 patients with confounders 
including concurrent corticosteroid use, disease severity and pubertal staging data unavailable 
41
.  Other studies have shown improvement in growth with both MTX monotherapy and used 
in combination with IFX; in a cohort of 12 patients MTX and IFX combination therapy was 
effective in improving linear growth 
2
 whilst MTX monotherapy consistently demonstrates 
improvement in height velocity 
42
. As yet, there is no mechanism proposed at to potential 
pathways which may explain this improvement in growth for either AZA or MTX.  
Children who received at least 12 months of therapy with IFX demonstrated improved 
linear growth compared to those who received induction only or stopped IFX before 12 
months. Potential explanations could be that those who continued treatment until 12 months 
were more likely to achieve remission (only 15% did not achieve remission) thereby having a 
reduction in inflammation resulting in improvement in linear growth.  This theory is 
supported by evidence from the REACH extension study which demonstrated an improved 
trend in those who continued with no disease (n=11) vs those with mild/moderate disease 
(n=39).  
Limited data exists on the effects of ADA on growth and is divided with only one 
RCT,  the Imagine trial, which found improvement in height velocity z scores at 6 and 12 
months in both the higher and lower doses of ADA, however, no pubertal data was 
provided
10
. A multicentre UK and Irish audit demonstrated improved short term growth and 
our results are similar to that study demonstrating an improvement in Δ height SDS at 6 
months after initiating ADA which continued in our cohort to 12months;  we did not observe 
the increase in height velocity previously observed 
23
. This UK and Irish study provided 
crucial pubertal data and showed improved growth in those in Tanner stage 1-3, however, we 
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found no such improvement in those who were prepubertal (Tanner stage 1) but significant 
improvement in those in Tanner stage 2 and 3 for Δ height SDS and height velocity 
suggesting that development through puberty may at least partially explain the improvement 
in height. No improvement was seen in those in Tanner 4 and 5 as would be expected and 
been previously shown
23
.  Data on lack of effect comes from a  single centre study from 
Israel which found no improvement in height at last follow up (median of 17.3 months) again 
no pubertal data was provided 
43
.  
Our results should be interpreted with a degree of caution; this population based study 
includes only those treated with anti-TNF therapy which undoubtedly represents the more 
severe end of the disease spectrum and where a relatively higher rate of growth failure would 
be expected.  Furthermore, satisfactory growth data was available for only 49% of our cohort 
of anti-TNF treated patients and full pubertal status data in 71% of these. As a ‘real life’ 
clinical experience from a nationwide group managed from 3 different centres over a 13 year 
period there is significant heterogeneity in the data due to changing treatment practices as 
new evidence emerged and differing rates of uptake of change within these centres; example 
of these include episodic dosing with IFX in 2000-2007
24
 and induction only moving to  
induction plus maintenance given improved outcomes in those that continued
44
.  Now 
treatment algorithms have changed considerably, IFX is given earlier on in treatment course 
in those patients with a severe phenotype such as those with widespread colonic deep 
mucosal ulceration, growth failure or severe perianal disease with episodic treatment 
abandoned and long term maintenance being the norm. Other studies have shown the benefit 
to early aggressive treatment in altering the disease progression
38
, so it is possible that if IFX 
is given earlier the somewhat modest improvement in growth seen in this study will become 
more pronounced.  
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The results of our large retrospective population-based cohort study shows growth 
failure is relatively common in the Scottish population who were treated with anti-TNF 
therapy, with 18% of pediatric patients who subsequently received anti-TNF therapy 
demonstrating severe growth failure at start of therapy. We have demonstrated that 
Infliximab and possibly Adalimumab are associated with improved linear growth at 12 
months after treatment start. In those treated with Infliximab most improvement is seen in 
those who achieved remission, had disease for longer than 2 years, received combination 
therapy with azathioprine, received maintenance therapy and were Tanner stages 1-3. For 
Adalimumab we have shown probable improvement in growth again in those who were 
Tanner stages 2 and 3. The exact role that anti-TNF therapy plays in improving growth 
requires further study, including elucidation of more effective treatment strategies to reduce 
the inflammatory process and promote catch-up growth, so ensuring that young people with 
IBD can achieve their full growth potential. 
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Figure 1- Status of patients in Scottish National biologicals registry over study period 
 
195 patients recieved 
anti-TNFs 
Infliximab 
n=191 
Crohns'd disease 
n=160 
114- induction plus 
maintainence 
46 induction only 
115 stopped 
65  had 12 month growth 
data 
25 had 24 month growth 
data 
15 had 36 month growth 
data 
49 still on at last follw up 
21 had 12 month growth 
data 
40 had 24 month 
grwowth data 
24 had 36 month growth 
data 
Inflammatory Bowel 
Disease Unclassified 
n=3 
2- induction plus 
maintenance 
1- induction only 
No 12 month  growth 
data 
Ulcerative Colitis 
n=28 
12- induction plus 
maintenance 
16 induction only 
8 stopped 
5 had 12 month growth 
data 
2 had 24 and 36month 
growth data 
4 still on at last follow up 
2 had 12 month growth 
data 
1 had 24 and 36 month 
growth data 
Adalimumab 
n=49 
(4 only recieved ADA) 
Crohn's Disease 
n=46 
35 still on at last follow 
up 
20 had 12 month growth 
data available 
11 stopped 
9 had 12 month grwoth 
data available 
Inflammatory Bowel 
disease Unclassified 
n=1 
No 12 month  growth 
data 
Ulcerative Colitis 
n=2 
No 12 month growth data 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Figure 2- Improvements in linear growth are seen at 12 months in those treated with Infliximab 
who achieve remission post induction (n=56) 
A. Improvement seen in median ht SDS at T+12 compared to T0 
 
B. Improvement seen in Delta ht SDS at T+12  
  
 
 p<0.001 
 p<0.001 
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C. Improvement seen in height velocity  
 
 
 
 
 
 
  
p=0.001 
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Figure 3. Tanner stage 1-3 shows improvement in height velocity and delta height SDS at T0 to 
T+12 without improvement in height SDS (n=24) 
A. Tanner stage 1 ht SDS shows no improvement in ht SDS at T+12 
 
 
 
B. Tanner stage 2&3 shows no improvement in ht SDS at T+12 (n=20) 
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C. Tanner stage 1 shows improved delta ht SDS at T+12 
 
 
D. Tanner stage 2&3 shows improvement in delta ht SDS at T+12 
 
 
  
p=0.004 
p=0.003 
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E. Tanner stage 1 shows improvement in Height Velocity at T+12 
 
 
 
F. Tanner stage 2 and 3 shows improvement in Height Velocity at T+12 
 
 
 
 p=0.007 
 p=0.01 
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Tables 
 
1.  Improved growth parameters seen at Baseline characteristics of 93 patients requiring 
Infliximab and 28 patients receiving ADA with satisfactory growth data for 24 
months; results are expressed as median (range) and number (%) 
 
2.  Long term follow up to 36 months shows no further improvement in height velocity 
and delta height SDS beyond 12 months with improvement seen in weight and BMI 
SDS at 12 months post-IFX treatment. 
3. 12 months in those treated with IFX (n=93) 
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Table 1 Baseline characteristics of 93 patients requiring Infliximab and 28 patients receiving ADA with full growth data for 24 months; results are expressed as median 
(range) and number (%)  
 
 IFX- Crohn’s disease (CD)  Ulcerative colitis (UC) ADA- Crohn’s disease (CD) Ulcerative colitis (UC) 
Number of patients 
-Female 
86 (92%) 
38 (44%) 
7 (7%) 
1 (14%) 
28(97%) 
12 (43%) 
1 (3%) 
1 (3%) 
Median age at diagnosis (range yrs.)  10.5 (2.72-15.1) 10.2 (8.48-14.7) 10.3 (4.89-14.9) 12.1 
Median Age at start of IFX (range 
yrs.) 
13.8 (5.9-16.9) 13.7 (9.2-17.6) 13.4 (6.8-17.2) 13.7 
Median Duration from diagnosis to 
start IFX (range yrs.) 
2.86 (0.15-9.45) 2.66 (0.78-5.6)  3.4 (0.04-8.4) 1.5 
Montreal classification 
 
L1 and L4 2 (2%)          B1 75 (87%) 
L2 15 (17%)                   B2 9 (10%) 
L2 and L4 12 (14%)      B3 2 (2%) 
L3 20 (23%) 
L3 and L4 36 (42%) 
L5 1 (1%) 
E1 0 
E2 1 (14%) 
E3 6 (86%) 
L2 9 (32%)                    B1 20 (71%) 
L2 and L4 3 (11%)       B2 5 (18%) 
L3 6 (21%)                    B3 3 (11%) 
L3 and L4 10 (36%) 
 
E1 0 
E2 0 
E3 1 (100%) 
Concomitant medications at IFX start 
- Corticosteroids 
- Methotrexate 
- Azathioprine/6-MP 
 
40 (47%) 
40 (47%) 
38 (44%) 
 
4 (57%) 
0 (0%) 
4 (57%) 
 
12 (43%) 
16 (57%) 
3 (11%) 
 
 
1 (100%) 
0 (0%) 
0 (0%) 
Indications to start IFX/ADA (more 
than 1 indication is possible) 
 
 Active Luminal disease 72 (84%) 
 Immunomodulator failure 65 (76%) 
 Bridge to immunosuppression 12 
(14%) 
 Perianal disease 16 (19%) 
Growth+/- pubertal delay 4 (5%) 
Chronic active UC 5(71%) 
Acute severe colitis 2 (29%) 
Steroid dependency 3 (43%) 
Immunomodulator failure 4 
(57%) 
IFX primary non responder 12 (41%) 
Loss of response to IFX 10 (36%) 
Allergic reaction 1 (3%) 
Family choice 2 (7%) 
Previous JIA 2 (7%) 
Possible JIA at CD diagnosis 1 (3%) 
IFX primary non 
responder 1 (100%) 
 
Disease severity at induction 
- Remission 
- Mild 
- Moderate/severe 
 
2 (2%) 
20 (24%) 
64 (74%) 
 
0 
0 
7 (100%) 
 
0 
8 (39%) 
20 (71%) 
 
0 
0  
1 (100%) 
Response post induction -Steroid free remission 35 (33%) 
-Remission 20 (24%) 
-Steroid free remission 
3(43%) 
-Steroid free remission 1 (4%) 
-Remission 4 (14%) 
-Steroid free remission 0 
-Remission 0 
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Response not remission 27 (31%) 
No response 9 (10%) 
Remission 1 (14%) 
Response but not yet 
remission 2 (29%) 
No response 1 (14%) 
Response but not yet remission 17 (61%) 
No response 6 (21%) 
Response but not yet 
remission 0 
No response 1 (100%) 
Prior medication usage 
- Corticosteroids 
- Methotrexate  
- Azathioprine/6-MP  
- Exclusive enteral nutrition 
- Adalimumab 
 
72 (84%) 
42 (49%) 
77 (90%) 
75 (86%) 
66 (77%) 
1 (1%) 
 
7 (100%) 
0 
14 (88%) 
0 
 
0 
 
25 (89%) 
20 (71%) 
25(89%) 
22 (79%) 
1 (1%) 
0 
 
1 (100%) 
1 (100%) 
1 (100%) 
0 
1 (100%) 
0 
Surgery 
Pre IFX 
 
 
 
 
 
Post IFX 
 
Small bowel resection 4 
Right hemicolectomy 2 
Left colonic resection 3 
Defunctioning stoma 1 
Perianal surgery 12 
Colectomy and end ileostomy 0 
 
Small bowel resection 0 
Right hemicolectomy 4 
Left colonic resection 2 
Defunctioning stoma 5 
Perianal surgery 7 
Colectomy and end ileostomy 10 
 
 
 
 
 
 
 
 
Defunctioning stoma 1 
Colectomy and end ileostomy 
3 
 
Small bowel resection 0 
Right hemicolectomy 0 
Defunctioning stoma 0 
Perianal surgery 7 
Colectomy and end ileostomy 0 
 
Small bowel resection 1 
Right hemicolectomy 1 
Defunctioning stoma 1 
Perianal surgery 1 
Colectomy and end ileostomy 3 
 
 
 
 
 
 
 
 
Colectomy and end 
ileostomy 1 
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Table 2 Long term follow up to 36 months shows no further improvement in height velocity and delta height SDS beyond 12 months with improvement 
seen in weight and BMI SDS at 12 months post-IFX treatment. 
 
 
 T-12 (n=42) T0 (n=42) P value for 
T-12 vs T0 
T+12 (n=42) P value for 
T0 vs T+12 
T+24 (n=42) P value 
T+12 vs 
T+24 
T+36 (n=42) P value 
For T+24 vs 
T+36 
Ht SDS -0.9 (-2.4,0.4) -1.0 (-2.9,0.04) P<0.0001 -1.1 (-2.6,-0.03) p=0.39 -0.9 (-2.5,-0.08) p=0.33 -0.8 (-
2.6,0.06) 
p=0.29 
Δ ht SDS n/a -0.25 (-0.7,0.2) n/a 0.07 (-0.5,0.4) p=0.009 0.08 (-0.4, 0.6) p=0.01 0.06 (0.3,0.6) p=0.90 
HV n/a 3.8 (1.2,7.1) n/a 4.8 (1.5,9.1) p=0.04 5.5 (0.9,8.8) p=0.79 4.8 (0.0,7.8) p=0.10 
Weight SDS* -0. 5 (-1.9,1.1) -0.6 (-1.9,1.1) p=0.001 -0.4 (-2.0,1.2) p=0.002     
BMI SDS* 0.1  (-1.6,1.5) -0.3 (-1.9,1.7) p=0.05 0.1 (-1.5,1.9) p=0.003     
HV= height velocity *n=94 
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Table 3 Improved growth parameters seen at 12 months in those treated with IFX (n=93) 
 Ht SDS T-12 
Median (IQR) 
Ht SDS T0 
Median (IQR) 
P value 
for T-12 
vs T0 
Ht SDS T+12 
Median (IQR) 
P value 
For T0 vs 
T+12 
Delta Ht SDS T0 
Median (IQR) 
Delta Ht SDS T+12 
Median (IQR) 
P value 
for 
DeltaT0 
vs Delta 
T+12 
Height 
Velocity T0 
Median (IQR) 
Height 
Velocity T+12 
Median (IQR) 
P value for 
Height 
Velocity 0 
vs Height 
Velocity 12 
Disease duration 
<2yrs 
Disease duration 
>2yrs 
-0.7 (-2.2, 0.7) 
 
-0.8 (-2.4,0.7) 
-0.8 (-2.4,0.4) 
 
-0.8 (-2.5, 0.8) 
P=0.002 
 
P=0.007 
-0.9 (-2.2,0.4) 
 
-0.7 (-2.4, 0.8) 
P=0.85 
 
P=0.005 
-0.3 (-0.8, 0.3) 
 
-0.1 (-0.6,0.3) 
0.03 (-0.5, 0.6) 
 
0.08 (-0.3, 0.6) 
P=0.01 
 
P<0.001 
3.3 (0.8, 6.9) 
 
3.6 (1.1,7.2) 
4.1 (0.9, 9.4) 
 
4.9 (1.3, 9.2) 
P=0.06 
 
P=0.01 
Gender 
-Males 
-Females 
 
-0.73 (-2.3,0.7) 
-0.8 (-2.3,1.1) 
 
-0.81 (-2.5,-0.5) 
-0.7 (-2.3,1.0) 
 
p<0.001 
p=0.07 
 
-0.9 (-2.4,0.6) 
-0.7 (-2.2,1.1) 
 
p=0.16 
p=0.10 
 
-0.2 (-0.7,0.2) 
-0.1 (-0.5,0.5) 
 
0.1 (-0.5,0.6) 
0.10 (-0.3,0.6) 
 
p<0.001 
p=0.01 
 
3.8 (1.0,7.3) 
3.2 (0.7,6.7) 
 
5.2 (2.6,9.6) 
3.2 (0.8,8.0) 
 
p=0.001 
p=0.41 
Moderate disease at 
baseline 
0.7 (-2.2,0.8) -0.7 (-2.5,0.5) <0.001 -0.8 (-2.3,0.7) p=0.23 -0.3 (-0.7,0.2) 0.04 (-0.5,0.6) p<0.001 2.9 (1.0,7.1) 4.4 (1.1,9.5) p=0.002 
Immunomodulator 
use 
No 
Immunomodulators 
-0.8 (-2.2,0.7) 
 
0.2 (-2.6,1.2) 
-0.9 (-2.5,0.5) 
 
-0.1 (-2.5,0.8) 
p<0.001 
 
p=0.33 
-0.9 (-2.3,0.7) 
 
-0.4 (-2.2,0.7) 
p=0.005 
 
p=0.16 
-0.2 (-0.6,0.3) 
 
-0.1 (-0.8,0.3) 
0.1 (-0.3,0.6) 
 
-0.2 (-0.7,0.5) 
p<0.001  
 
p=0.5 
3.5 (1.1,7.2) 
 
5.0 (0.0,7.1) 
4.9 (1.6,9.3) 
 
3.5 (0.0, 5.2) 
p=0.001 
 
p=0.53 
Azathioprine at 
baseline 
Methotrexate at 
baseline 
-0.4 (-2.4,0.9) 
 
-0.9 (-2.2,0.3) 
-0.7 (-2.8,0.7) 
 
-1.0 (-2.4,0.2) 
p=0.002  
 
p=0.02 
-0.7(-2.4,0.9) 
 
-1.0 (-2.0, 0.3) 
p=0.03 
 
p=0.06 
-0.3 (-0.7,0.3) 
 
-0.1 (-0.5,0.4) 
0.1 (-0.3,0.6) 
 
0.05 (-0.4,0.8) 
p<0.001  
 
p=0.002 
3.0 (1.0,7.3) 
 
4.1 (1.2, 7.1) 
4.6 (1.3,9.3) 
 
5.3 (1.8,9.4) 
p=0.005 
 
p=0.03 
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Induction only 
Induction plus 
maintenance 
IFX at 12 mths 
-0.8 (-2.5,0.9) 
-0.7 (-1.9,0.6) 
 
-0.7 (1.8,0.5) 
-0.9 (-2.6,0.9) 
-0.8 (-2.3,0.5) 
 
-0.8 (-2.4,0.5) 
p=0.009 
p=0.002 
 
p=0.001 
-1.1 (-2.4,0.8) 
-0.8 (-2.3,0.6) 
 
-0.8 (-2.0,0.4) 
p=0.93 
p=0.02 
 
p=0.03 
-0.3 (-0.7,0.3) 
-0.1 (-0.6,0.3) 
 
-0.2 (-0.6,0.3) 
0.04  (-0.4,0.6) 
0.10 (-0.4,0.6) 
 
0.1 (-0.5,0.7) 
p=0.003 
p<0.001 
 
p<0.001 
3.0 (0.6,6.4) 
3.8 (1.1,7.3) 
 
3.8 (1.4,7.3) 
3.5 (1.1,9.6) 
5.0 (1.2,9.0) 
 
5.8  (2.0,9.7) 
p=0.17 
p=0.004 
 
p=0.001 
Corticosteroid use 
baseline 
Corticosteroid free 
baseline 
-0.4 (-2.0,1.4) 
 
-0.9 (-2.4,0.4) 
-0.5 (-2.7,1.1) 
 
-1.0 (-2.4,0.5) 
p<0.001 
 
p=0.21 
-0.5 (-2.3,1.1) 
 
-0.9 (-2.3,0.3) 
p=0.29 
 
 p=0.05 
-0.3 (-0.7,0.2) 
 
-0.08 (-0.4,0.5) 
0.05 (-0.5,0.6) 
 
0.06 (-0.4,0.6) 
p<0.001 
 
p=0.01 
2.7 (0.9,6.1) 
 
4.3 (1.2,7.3) 
4.4 (1.4,9.4) 
 
4.9 (1.1,9.5) 
P=0.001 
 
p=0.30 
Surgery -0.74 (-2.4,0.6) -0.8 (-2.3,0.5) P=0.006 -1.0 (-2.6,0.3) P=0.15 -0.20 (-0.7,0.3) -0.1 (-0.5,0.4) P=0.065 3.4 (0.9,7.1) 4.0(1.0,8.0) P=0.17 
No surgery -0.7 (-2.2,0.8) -0.8 (-2.5,0.8) P=0.002 -0.8 (-2.2,0.8) P=0.001 -0.17 (-0.6,0.3) 0.1 (-0.3,0.6) P<0.001 3.5 (1.1,7.3) 4.9 (1.3,9.5) P=0.005 
 
